Does vasopeptidase inhibition with omapatrilat increase fluid and protein microvascular permeability in cat skeletal muscle?
A clinically relevant antihypertensive dose of omapatrilat reduces vascular resistance and increases fluid and protein permeability, the permeability effect more by inhibition of NEP than by inhibition of ACE, by a mechanism involving bradykinin.
Our findings suggest upregulated expression of SDF-1 and its receptor CXCR4 in degenerated IVD.